Investment Rating - The report indicates a positive investment outlook for the consumer-grade 3D printing industry, highlighting significant growth potential driven by various demand factors and technological advancements [3][79]. Core Insights - The consumer-grade 3D printing market is expected to reach USD 7.1 billion by 2028, with a compound annual growth rate (CAGR) of 19.2% from 2022 to 2028 [3][83]. - Key demand drivers include the rise of the maker movement in Europe and the U.S., the DIY culture, and the increasing consumer interest in personalized products [3][39]. - The supply side is characterized by technological advancements, a diverse material spectrum, and the establishment of community ecosystems that enhance customer engagement [3][91]. Summary by Sections 1. Market Overview - The consumer-grade 3D printing market is primarily designed for individual users and small businesses, offering ease of use and lower costs compared to industrial-grade printers [3][10]. - The market is witnessing rapid growth, with significant contributions from the U.S. and European markets, driven by high consumer spending power and interest in technology [3][47]. 2. Demand Drivers - The report identifies four main demand drivers: 1. The "garage innovation" culture in the U.S. and Europe, which promotes the adoption of desktop devices [3][39]. 2. The DIY trend among consumers, allowing for personalized product creation [3][40]. 3. The tool-like attributes of 3D printers for small businesses and educational institutions [3][59]. 4. The influence of trendy collectible products that enhance consumer interest [3][70]. 3. Supply Trends - The supply side is evolving with advancements in technology, including multi-functional devices and AI integration, which lower operational barriers for users [3][91]. - The materials used in 3D printing are becoming more diverse, allowing for a wider range of applications [3][106]. - Community ecosystems are being built to retain customer loyalty and encourage new entrants through crowdfunding opportunities [3][110]. 4. Key Players - Core companies identified in the report include: 1. Key components: Jieput, Ruike Laser, and Jinchengzi [3]. 2. 3D scanning accessories: Sikan Technology and Orbbec [3]. 3. Materials: Haizheng Materials, Huitong Technology, and Jialian Technology [3]. 4. Complete machines: Anker Innovation and others [3][28]. 5. Market Statistics - In 2024, China's 3D printer exports are projected to reach USD 1.147 billion, with a year-on-year growth of 31.09% [3][80]. - The report notes that over 90% of entry-level 3D printers globally are supplied by Chinese manufacturers, indicating a strong competitive position in the market [3][88].

General Principles - The management system for the resignation of directors and senior management at Zhejiang Haizheng Biological Materials Co., Ltd. aims to standardize the resignation process and ensure corporate governance stability and shareholder rights [1][2] - This system applies to all directors (including independent directors) and senior management personnel of the company [1] Resignation Circumstances and Effectiveness - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the board [3][4] - The company must complete the election of new directors within 60 days of a resignation to ensure compliance with legal and charter requirements [2][4] - Non-employee representative directors are elected by the shareholders' meeting, while employee representative directors are elected by the employee representative assembly [2] Responsibilities and Obligations of Resigning Directors and Senior Management - Resigning directors and senior management must ensure a proper handover of work and may be subject to exit audits [5][6] - The company will track and supervise the fulfillment of any public commitments made by resigning directors and senior management during their tenure [5][6] - The fiduciary duties of directors and senior management continue for six months after resignation, and they remain liable for any breaches during their tenure [6][7] Additional Provisions - The system stipulates that directors and senior management must comply with relevant laws and regulations, and any violations resulting in losses to the company will incur liability [6][7] - The system will take effect upon approval by the company's board and will be interpreted by the board [7]

Core Viewpoint - Zhejiang Haizheng Biological Materials Co., Ltd. has decided to abolish its supervisory board and transfer its responsibilities to the audit committee of the board of directors, aiming to enhance internal governance and operational efficiency [1][2][3]. Group 1: Board Meeting Decisions - The seventh board of directors held its sixteenth meeting on July 15, 2025, with all 8 directors present, confirming the legality and validity of the meeting [1]. - The board approved the proposal to cancel the supervisory board and amend the company's articles of association and related governance documents [1][2]. - The board also approved the revision and establishment of several corporate governance systems to align with the cancellation of the supervisory board [2][3]. Group 2: Voting Results - All proposals discussed during the meeting received unanimous support, with 8 votes in favor and no votes against or abstentions [2][3][4]. Group 3: Director Changes - The board accepted the resignation of director Wang Haiyan and nominated Wang Fang as a candidate for the board, pending approval at the upcoming shareholders' meeting [3][4]. - Wang Fang will also be elected as a member of the remuneration and assessment committee upon her approval as a director [4]. Group 4: Upcoming Shareholders' Meeting - The board has scheduled the second extraordinary shareholders' meeting for July 31, 2025, to review the matters discussed in the board meeting [4].

Meeting Information - The second extraordinary general meeting of shareholders for 2025 will be held on July 31, 2025, at 14:00 at the conference room of Zhejiang Hainuoer Biomaterials Co., Ltd. [1][2] - The meeting will adopt a combination of on-site voting and online voting through the Shanghai Stock Exchange's network voting system [2][4]. Voting Procedures - Shareholders can vote through the Shanghai Stock Exchange's network voting system from 9:15 to 15:00 on the day of the meeting [1][4]. - Specific voting procedures for margin trading, transfer, and other related accounts must comply with relevant regulations [2]. Agenda Items - The meeting will review several non-cumulative voting proposals, including amendments to the company's funding management system and the election of a non-independent director [2][3][10]. - All proposals have been approved by the company's seventh board of directors at its sixteenth meeting [2]. Attendance and Registration - Shareholders must register to attend the meeting, either in person or by authorizing a proxy [5][8]. - Registration must be completed by July 29, 2025, for non-on-site attendees [5][10]. Communication and Reminders - The company will utilize a reminder service to notify shareholders about the meeting and voting procedures [9][10]. - Contact information for inquiries includes a phone number and email address for shareholder assistance [10].

证券代码：688203 证券简称：海正生材 公告编号：2025-39 浙江海正生物材料股份有限公司 根据《公司法》《公司章程》及相关规定，王海燕女士辞职后不会导致公司 董事会成员低于法定最低人数，不会影响董事会依法规范运作，也不会影响公司 正常的经营发展，王海燕女士的辞职报告自送达公司董事会之日起生效。 截至本公告披露之日，王海燕女士未持有公司股份，不存在应当履行而未履 行的承诺事项。公司董事会对王海燕女士在任职期间为公司发展作出的贡献表示 衷心感谢！ 二、补选董事候选人的情况 关于公司董事辞职暨补选董事候选人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江海正生物材料股份有限公司（以下简称"公司"）董事会近日收到王海 燕女士提交的书面辞职报告。因工作需要，王海燕女士辞去公司董事、董事会薪 酬与考核委员会委员职务，王海燕女士辞职后将不再担任公司任何职务。根据控 股股东浙江海正集团有限公司推荐，董事会提名委员会审核通过了董事候选人任 职资格，董事会同意提名王芳女士为公司第七届董事会董事候选人，该议案尚 ...

证券代码：688203 证券简称：海正生材 公告编号：2025-38 浙江海正生物材料股份有限公司 关于取消监事会、修订《公司章程》及修订和制定部 分公司治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江海正生物材料股份有限公司（以下简称"公司"）于 2025 年 7 月 15 日召开第七届董事会第十六次会议审议通过了《关于取消监事会并修订<公司章 程>及其附件的议案》、《关于修订和制定部分公司治理制度的议案》，现将相 关情况公告如下： 一、取消监事会的相关情况 根据《中华人民共和国公司法》《上市公司章程指引》《上海证券交易所科 创板股票上市规则》等最新规定，结合公司实际情况，公司将不再设置监事会， 监事会的职权由董事会审计委员会行使，《浙江海正生物材料股份有限公司监事 会议事规则》等监事会相关制度相应废止。同时，公司依据相关规则对《公司章 程》中其他条款进行修订，亦相应修订《公司章程》附件《股东会议事规则》及 《董事会议事规则》。公司监事会取消后，公司监事徐伟、张颖婷、叶海燕（职 工代表监事）不再担任公 ...

证券代码：688203 证券简称：海正生材 公告编号：2025-40 浙江海正生物材料股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 召开地点：浙江省台州市台州湾新区台州湾大道 188 号浙江海诺尔生物材 料 有限公司会议室 （七） 涉及公开征集股东投票权 股东会召开日期：2025年7月31日 本次股东会采用的网络投票系统：上海证券交易所股东大会网络投票系 统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 7 月 31 日 14:00:00 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 31 日 至2025 年 7 月 31 日 采用上海证券交易所网络投票 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江海正生物材料股份有限公司（以下简称"公司"）第七届董事会第十六 次会议于 2025 年 7 月 15 日上午以通讯方式召开，会议通知已于 2025 年 7 月 9 日以电子邮件方式送达全体董事。会议应出席董事 8 人，实际出席董事 8 人，公 司监事及高级管理人员列席会议，本次会议的召集、召开程序和方式符合《公司 法》和《公司章程》的有关规定，会议决议合法、有效。本次会议由董事长郑柏 超先生主持，经与会董事认真讨论研究，会议审议并通过了如下决议： 一、审议通过《关于取消监事会并修订<公司章程>及其附件的议案》 根据相关法律法规、规范性文件的有关规定，结合公司实际情况，公司不再 设置监事会，监事会的职权由董事会审计委员会行使，公司《监事会议事规则》 等监事会相关制度相应废止，同时修订《公司章程》《股东会议事规则》《董事 会议事规则》。 具体内容详见公司于同日在上海证券交易所网站(www.sse.com.cn)披露的 《浙江海正生物材料股份有限公司关于取消监事会、修订<公司章 ...

第一章 总则 浙江海正生物材料股份有限公司董事、高级管理人员离职管理制度 浙江海正生物材料股份有限公司 董事、高级管理人员离职管理制度 第三条 董事可以在任期届满以前辞任。辞任应向董事会提交书面辞职报告， 公司收到辞职报告之日辞任生效，公司将在两个交易日内披露有关情况。 第四条 如存在以下情形的，在改选出的董事就任前，原董事仍应当依照法 律、行政法规、部门规章和《公司章程》规定，履行董事职务，但存在相关法规 另有规定的除外： （一）董事任期届满未及时改选，或者董事在任期内辞任导致公司董事会成 员低于法定最低人数； 第一条 为规范浙江海正生物材料股份有限公司（以下简称"公司"）董事、 高级管理人员离职管理，保障公司治理稳定性及股东合法权益，根据《中华人民 共和国公司法》《上市公司章程指引》和《浙江海正生物材料股份有限公司章程》 （以下简称《公司章程》）及其他有关法律、法规的规定，制定本制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员的辞任、 任期届满、解任以及其他导致董事、高级管理人员实际离职等情形。 第二章 离职情形与生效条件 （二）审计委员会成员辞任导致审计委员会成员低于法定最低人数，或 ...

浙江海正生物材料股份有限公司董事会提名委员会工作细则 浙江海正生物材料股份有限公司 董事会提名委员会工作细则 第一章 总 则 第一条 为规范浙江海正生物材料股份有限公司（以下简称"公司"）董事、 高级管理人员的产生，完善公司治理结构，根据《中华人民共和国公司法》、《浙 江海正生物材料股份有限公司章程》（以下简称"公司章程"）及其他有关规定， 公司特设立董事会提名委员会，并制定本细则。 第二条 董事会提名委员会是董事会设立的专门工作机构，主要负责对公司 董事和高级管理人员的人选、选择标准和程序进行审查、选择并提出建议。 第二章 人员组成 第三条 提名委员会由三名董事组成，其中包括两名独立董事。 第四条 提名委员会委员由董事长、二分之一以上独立董事或者三分之一以 上董事提名，并由董事会选举产生。 第五条 提名委员会设召集人一名，由独立董事委员担任，负责主持委员会 工作；委员会召集人在委员内选举，并报请董事会批准产生。 第六条 提名委员会委员任期与公司董事任期一致，委员任期届满，连选可 以连任。期间如有委员不再担任公司董事职务，自动失去委员资格，并由委员会 根据上述第三条至第五条规定补足委员人数。 第三章 职责权限 ...